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ABSTRACT: The absence of an intestinal absorption sink is a significant weakness of standard in vitro lipolysis methods, potentially
leading to poor prediction of in vivo performance and an overestimation of drug precipitation. In addition, the majority of the
described lipolysis methods only attempt to simulate intestinal conditions, thus overlooking any supersaturation or precipitation of
ionizable drugs as they transition from the acidic gastric environment to the more neutral conditions of the intestine. The aim of this
study was to develop a novel lipolysis method incorporating a two-stage gastric-to-intestinal transition and an absorptive
compartment to reliably predict in vivo performance of lipid-based formulations (LBFs). Drug absorption was mimicked by in situ
quantification of drug partitioning into a decanol layer. The method was used to characterize LBFs from four studies described in the
literature, involving three model drugs (i.e., nilotinib, fenofibrate, and danazol) where in vivo bioavailability data have previously been
reported. The results from the novel biphasic lipolysis method were compared to those of the standard pH-stat method in terms of
reliability for predicting the in vivo performance. For three of the studies, the novel biphasic lipolysis method more reliably predicted
the in vivo bioavailability compared to the standard pH-stat method. In contrast, the standard pH-stat method was found to produce
more predictive results for one study involving a series of LBFs composed of the soybean oil, glyceryl monolinoleate (Maisine CC),
Kolliphor EL, and ethanol. This result was surprising and could reflect that increasing concentrations of ethanol (as a cosolvent) in
the formulations may have resulted in greater partitioning of the drug into the decanol absorptive compartment. In addition to the
improved predictivity for most of the investigated systems, this biphasic lipolysis method also uses in situ analysis and avoids time-
and resource-intensive sample analysis steps, thereby facilitating a higher throughput capacity and biorelevant approach for
characterization of LBFs.
KEYWORDS: lipolysis, biphasic dissolution, lipid-based formulations, in vitro digestion, absorption, in vitro−in vivo relationship (IVIVR)
1. INTRODUCTION
The increasing trend toward the development of poorly water-
soluble drug candidates has created significant challenges for
pharmaceutical scientists to formulate a medicinal product
with adequate oral bioavailability. One way to overcome the
solubility limitations of emerging drug candidates is through
the use of lipid-based formulations (LBFs).1−5 Although LBFs
have become an important bioenabling approach in develop-
ment, the range of LBF classes and excipient considerations
pose many challenges with a high level of uncertainly with
respect to the selection of an optimal LBF formulation
design.6−8 Guidelines on the classification of LBFs9 and risk-
based assessments of LBFs10 have been proposed. However,
although these guidelines are useful, there is still a lack of in
vitro methods that reliably can predict or even rank the in vivo
performance of LBFs. This lack of predictive and high-
throughput in vitro tests hampers the efficient development of
LBFs. The current in vitro setups to assess the performance of
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LBFs have many limitations and often produce results which
are quite distinct from the in vivo performance.1,11,12
Commonly, LBFs are tested for their dispersibility, micellar
size, and behavior upon digestion, in line with the lipidic
formulation classification system proposed by Pouton.13 The
pH-stat lipolysis method is the most widespread standard
method for in vitro assessment of LBFs.14 It typically involves
the dispersion of an LBF in a medium representing the fasted
intestinal environment with the addition of digestive lipases
while controlling pH throughout the experiment by the
addition of a NaOH solution. After centrifugation of samples,
the drug in the different digestive phases (aqueous micellar
phase, solid precipitate, and the lipid phase) can be quantified.
The aqueous micellar phase contains the solubilized drug, bile
salts, phospholipids, cholesterol, and digested lipids. The solid
precipitate comprises the precipitated drug and insoluble Ca2+/
fatty acid (FA) soaps. The lipid phase consists of the drug and
undigested or partially digested lipids. However, the standard
pH-stat method has three major limitations. It is lacking an
absorptive sink, so the method does not mimic absorption of
the drug. As a result, drug concentrations in the digest media
are likely to exceed physiological concentrations within the
intestine, potentially leading to an overestimation of the risk of
luminal precipitation and consequentially leading to poor in
vitro−in vivo relationships (IVIVRs).11,15 In addition, as the
majority of pH-stat experiments are only conducted in
conditions mimicking the intestine, they can fail to adequately
capture supersaturation or precipitation of the drug upon
transition from the stomach into the small intestine. This is
especially important for weakly basic drugs, which are much
more soluble at gastric pH and prone to precipitate upon entry
into the small intestine. Finally, the pH-stat experiments are
very laborious involving time-consuming steps, including
centrifugation of samples and off-line high-performance liquid
chromatography (HPLC) analysis. This low-throughput
capacity of the setup is particularly limiting as a screening
tool for new LBFs in an industrial development setting, and the
sampling with off-line analytics allows only for a limited time
resolution to analyze kinetic concentration changes.
Several groups have proposed various modifications in an
effort to improve the biorelevance of in vitro lipolysis testing.
Fernandez et al. proposed a two-stage lipolysis procedure with
the incorporation of a gastric sector at pH 5.5 using
recombinant dog gastric lipase before transitioning to intestinal
conditions.16−18 Sassene et al. also proposed the incorporation
of a gastric sector using gastric lipase enzymes into the lipolysis
setup.19 The use of an organic layer to mimic absorption in the
small intestine during in vitro testing has been employed using
a compendial dissolution apparatus to assess LBFs.20,21 As the
drug partitions into the organic layer, this helps to maintain
sink conditions in the aqueous phase, thus facilitating ongoing
dissolution of any undissolved or precipitated drug present.
However, these setups did not simulate the digestion process
and only examined the release of the drug from the
formulation. Therefore, the impact of LBF digestion on
supersaturation and precipitation was not considered by these
methods. Absorption of the drug in the small intestine has
been incorporated into lipolysis testing using both artificial and
cellular membranes. Bibi et al. employed a PermeaPad system
to simulate absorption in the intestine during lipolysis testing
using a biomimetic membrane,22 whereas Keemink et al.23 and
Alvebratt et al.24 used a Caco-2 cell system to simulate
absorption in the small intestine during lipolysis testing.
Finally, by integrating data from a standard pH-stat setup,
Stillhart and Kuentz used an in silico biopharmaceutical
modeling approach to predict the impact of digestion of
LBFs under simulated continuous absorption sink condi-
tions.12
Despite these recent innovations in lipolysis testing, there is
still a need for a rapid and biorelevant in vitro lipolysis method
to screen LBFs during the formulation development phase to
address the change of pH (gastric to intestinal), lipid digestion,
and concurrent permeation through the intestinal epithelium.
The objective of this study was therefore to develop a new and
quick two-stage small-scale biphasic in vitro lipolysis protocol,
which incorporates dispersion in the gastric sector, gastro-
intestinal (GI) transit with the absorption of the drug and
possible digestion products in the small intestine to act as an
effective screening tool for novel LBFs. The addition of a
decanol layer for the intestinal sector was intended to mimic
absorption as the drug and post digestion products partition
into the decanol layer. Biphasic dissolution testing using an
inForm instrument (Pion Inc., MA, USA) has previously been
employed to test other bioenabling formulations,25,26 with
strong correlations found to in vivo data. The high level of
automation on the platform, including in situ pH control and
drug quantification, reduces human experimental errors and
makes the setup interesting for lipolysis testing. Evaluation was
performed by relating in vitro data collected with the novel
methodology with four previously published studies that
characterized a range of LBFs in vitro and in vivo.11,27−29
This included studies involving one weakly basic drug
(nilotinibpKa 2.1, 5.4)27 and two neutral drugs (fenofibrate
and danazol) with corresponding in vivo pharmacokinetic (PK)
data from rats,27 pigs,11 dogs,28 and humans.29 The results
from the two-stage biphasic lipolysis test were compared to
both the in vivo data and the most commonly applied in vitro
methodology (pH-stat method) of identical LBFs.
2. MATERIALS
Nilotinib and danazol were obtained from Kemprotec Ltd.
(Cum, UK). Fenofibrate and decanol were obtained from
Acros Organics (Geel, Belgium). Ethanol, olive oil, Tween 85,
Kolliphor EL, soybean oil, tris(hydroxymethyl)aminomethane,
calcium chloride dihydrate, taurodeoxycholic acid (NaTDC),
and pancreatic lipase (8 × USP) were obtained from Sigma-
Aldrich (Dorset, UK). Kolliphor RH 40 was obtained from
BASF (Ludwigshafen, Germany). Miglyol 812 was sourced
from IOI Oleochemical (Witten, Germany). Super refined
polysorbate 20-LQ and Tween 80 HP were obtained from
Croda Inc. (NJ, USA). Maisine CC and Peceol were kindly
donated from Gattefosse ́ (Saint-Priest, France). Capmul MCM
and Captex 1000 were kindly donated by ABITEC
Corporation (Ohio, USA). SIF powder was obtained from
biore l evan t . com (London , UK) . Mi l l i -Q wate r
(18.2 MΩ cm−1) was used for the experimental work. All
other chemicals and solvents were of analytical grade or HPLC
grade and purchased from VWR, UK.
3. METHODS
3.1. Preparation of Media. Concentrated intestinal media
(10× concentrated) were prepared using SIF powder and 20
mM Tris buffer, containing 1.4 mM calcium chloride and 150
mM NaCl. SIF powder (1.12 g) was added to 25 mL of the
buffer and stirred until the powder was dissolved. This was
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made up to volume (50 mL) with the buffer and left to stand
for 2 h before usage. The gastric media consisted of dilute HCl
at pH 2, containing 1.4 mM calcium chloride and 150 mM
NaCl.
The porcine pancreatic extract was prepared freshly
immediately prior to each lipolysis experiment by adding 1 g
of porcine pancreatic enzymes (8 × USP) to 5 mL of blank
media (consisting of 1.4 mM calcium chloride and 150 mM
NaCl) at 5 °C and vortexed thoroughly. This mixture was then
centrifuged at 2800g for 15 min, with the supernatant used as
the porcine pancreatic extract for the lipolysis experiments.
3.2. Preparation of the LBFs. The respective LBFs were
prepared according to the methods outlined in the original
research articles,11,27−29 with the composition of each
formulation shown in Table 1a−d. The nomenclature assigned
to each formulation in this study replicates the original
research articles. The drug dose-to-lipid ratios were maintained
exactly as per the administered LBFs in the in vivo testing. The
dose of each LBF delivered was scaled down relative to the 40
Table 1. Overview of the Composition of the (a) Nilotinib LBFs,27 (b) Fenofibrate LBFs from the Pig Study,11 (c) Fenofibrate
LBFs from the Human Study,29 and (d) Danazol LBF28
(a)
nilotinib LBF from the rat study27
formulation name Peceol Capmul MCM Captex 1000 olive oil
formulation category type I type I type I type I
formulation type suspension suspension suspension suspension
Peceol (%) 100 - - -
Capmul MCM (%) - 100 - -
Captex 1000 (%) - - 100 -
olive oil (%) - - - 100
drug concentration (mg/mL) 10 10 10 10
LBF dose per experiment (g) 1 1 1 1
nilotinib dose (mg) per lipolysis experiment 10.62 10.97 10 10.64
(b)
fenofibrate LBF from the pig study11
formulation name type IIIA MC type IIIA LC type IIIB/IV
formulation category type IIIA type IIIA type IIIB/IV
formulation type solution solution solution
Miglyol (%) 40 - -
olive oil (%) - 40 -
Tween 85 (%) 40 40 67
Cremophor RH (%) 20 20 33
fenofibrate concentration (mg/g) 80 80 80
LBF dose per experiment (g) 0.4 0.4 0.4
fenofibrate dose (mg) per lipolysis experiment 32 32 32
(c)
fenofibrate LBF from the human study29
formulation name E5 (80) E5 (20) MDS
formulation category type IIIA type IIIA type IIIA
formulation type solution solution suspension
fenofibrate (%) 10 10 20
Myritol 318 (%) 25 25 27.5
TPGS (%) 12 12 9.5
Tween 20 (%) - 48 38
Tween 80 (%) 48 - -
H2O (%) 5 5 5
LBF dose per experiment (g) 0.54 0.54 0.27
fenofibrate dose (mg) per lipolysis experiment 54 54 54
(d)
danazol LBF from the dog study28
formulation name F1 F2 F3 F4
formulation category type IIIA type IIIA type IIIB type IIIB/IV
formulation type solution solution solution solution
soybean/Maisine CC (1:1 w/w) (%) 60 37.5 18 -
Kolliphor EL (%) 30 55 64 65
ethanol (%) 10 7.5 18 35
drug load (mg/g) (80% saturated solubility) 11.8 16.1 17.8 18
LBF dose per experiment (g) 1 1 1 1
danazol dose (mg) per lipolysis experiment 11.8 16.1 17.8 18
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mL lipolysis volume used in this study, keeping the same lipid
formulation-to-volume ratio from any previous pH-stat testing
carried out on these LBFs. For example, 1.5 g of nilotinib LBF
in 60 mL of digestion media in the pH-stat experiment was
scaled down to 1 g of LBF to 40 mL of media in the biphasic
lipolysis experiment.
Briefly, the nilotinib suspensions were prepared by adding 10
mg to 1 mL of the lipid excipient with stirring overnight at 37
°C.27 The fenofibrate lipid solutions based on the pig study
were prepared by adding fenofibrate to the lipid excipients and
stirring at 50 °C for 30 min before stirring at 37 °C
overnight.11 To prepare the fenofibrate formulations from the
human study (two solutions and one suspension), the
excipients were added into a glass vial and heated to 80
°C.29 Fenofibrate for the micronized dispersion system (MDS)
formulation was prepared by sieving fenofibrate through a 40
μm analytical sieve. The sieved fenofibrate was added to the
lipid blends and stirred at 37 °C overnight. The danazol lipid
solutions were prepared by adding the lipid excipients and
danazol into a vial, followed by stirring at 50 °C for 10 min.28
This was subsequently cooled to ambient temperature before
ethanol was added and stirred overnight at 37 °C.
3.3. Biphasic Lipolysis. The biphasic lipolysis experiments
were carried out using the inForm (Pion Inc.) instrument at 37
°C, with the experimental setup shown in Figure 1 and the
dimensions of the setup given in the Supporting Information
(Table S1). The LBFs were initially dispersed into 32 mL of
simulated gastric media (pH 2), composed of dilute HCl, 1.4
mM calcium chloride, and 150 mM NaCl. Stirring was set to
300 rpm for the gastric sector to ensure adequate dispersion of
the LBFs.
After 30 min to simulate the transition into an intestinal
environment, concentrated FaSSIF (4 mL) was added. The pH
of the media was adjusted to 7.5 using 0.5 M NaOH, with the
pH controlled in situ throughout the intestinal sector to 7.5 ±
0.1 by the inForm instrument using 0.5 M NaOH. The
composition of the final aqueous intestinal fluid contained
sodium taurocholate (3 mM), phosphatidylcholine (0.75 mM),
Tris base (2 mM), NaCl (150 mM), and calcium chloride (1.4
mM). Digestion was initiated by addition of the pancreatic
extract (4 mL), which was dispersed for 1 min prior to the
addition of the decanol layer (40 mL). Stirring was temporarily
stopped, while decanol was added into the vessel. Stirring was
set to 100 rpm for the intestinal sector. After 60 min, the pH
was titrated back to pH 9 to determine the release of
nonionized free FAs.
The drug concentrations in the decanol layer were
quantified using an in situ fiber-optic multiwavelength dip
probe,24 with the relevant detection wavelengths shown in the
Supporting Information (Table S2). A linear calibration curve
was established between drug concentration and UV
absorbance (R2 > 0.99). Calibration standards were analyzed
in the same medium as the experimental setup. An excellent fit
was found when comparing spectra recorded from the
experimental runs with the standard spectra, with a root-
mean-square deviation of <0.01 in each case. This confirmed
the suitability of the in situ fiber-optic multiwavelength dip
probe for quantifying the drug concentration under the
proposed experimental conditions.
A summary of the biphasic lipolysis experimental conditions
and a comparison with the pH-stat experimental conditions
from the original research articles11,27,28 is shown in Table 2.
3.4. pH-Stat Testing of Fenofibrate LBFs Previously
Studied in Humans. As pH-stat testing had not previously
been carried out on the fenofibrate LBFs previously studied in
humans, these were completed to facilitate a comparison
Figure 1. Schematic of the biphasic lipolysis dissolution setup.
Table 2. Comparison of the Different in Vitro Lipolysis Experimental Conditions
biphasic lipolysis pH stat (this study) Koehl et al. pH stat27 Griffin et al. pH stat11 Cuine et al. pH stat28


















after addition of pan-
creatic enzymes
40 40 60 100 40
intestinal pH 7.5 7.5 7.5 7.5 7.5
buffer Tris (2 mM) Tris (2 mM) Tris (2 mM) Tris (50 mM) Tris (50 mM)
sodium chloride concen-
tration (mM)
150 150 150 150 150
calcium chloride con-
centration (mM)
1.4 1.4 1.4 5 5
absorption component decanol layer (40 mL) N/A N/A N/A N/A
gastric sector dilute HCl N/A N/A N/A N/A
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between all the results from the biphasic lipolysis setup with
the pH-stat method. The experimental protocol was adapted
from Koehl et al.,27 with the digestion volumes scaled down to
match the biphasic lipolysis testing volumes (40 mL). Testing
was completed using a pH-stat apparatus (Metrohm AG,
Herisau, Switzerland) comprising a Titrando 907 stirrer, an
804 Ti-stand, a pH electrode (Metrohm), and two 800 Dosino
dosing units coupled to a 20 mL autoburette. The system was
operated by the Tiamo 2.2 software (Metrohm). The
composition of the aqueous intestinal media was sodium
taurodeoxycholate (3 mM), phosphatidylcholine (0.75 mM),
Tris base (2 mM), NaCl (150 mM), and calcium chloride (1.4
mM). The pancreatin extract (USP × 8) for the pH-stat
experiments was reconstituted immediately prior to use using
the aqueous intestinal media and centrifuged at 2800g for 15
min at 5 °C. Initially, the LBF was introduced into 39 mL of
the aqueous intestinal media at 37 °C for 10 min to allow
adequate dispersion of the formulation, with samples (1 mL)
taken at 2.5, 5, and 10 min. To initiate the digestion process, 4
mL of the pancreatin extract was added. Samples (1 mL) were
taken at 5, 10, 15, 30, 45, and 60 min during the digestion
phase of the experiment. In each sample, enzymes were
inhibited by the addition of 1 M 4-bromophenylboronic acid in
methanol (5 μL per mL of the sample). The pH of the media
was controlled to pH 7.5 throughout the experiment using 0.6
M NaOH. After 60 min of digestion, the pH was titrated back
to pH 9 to determine the release of nonionized free FAs.
Samples were centrifuged at 37 °C and 21,000g for 30 min
using a benchtop centrifuge (Hettich MIKRO 200R). HPLC
analysis was carried out using an Agilent 1200 series HPLC
system (Agilent, CA, USA) comprising a binary pump,
degasser, autosampler, and variable wavelength detector
using a Waters Symmetry C18 column (4.6 × 150 mm, 5
μm) with a flow rate of 1 mL/min. Data analysis was done with
EZChrom Elite version 3.2 (Agilent). The mobile phase was
composed of an 80:20 mixture of acetonitrile/25 mM sodium
acetate buffer at pH 5. The detection wavelength was 287 nm.
A linear relationship was established between drug concen-
tration and area under the peak (R2 > 0.999) in the range of
0.1−25 μg/mL.
3.5. Data Extraction from Published Data. To facilitate
a comparison of the pH-stat and biphasic lipolysis results for
the danazol LBFs, the percentage of drug in the aqueous
micellar phase of the pH-stat experiment after 60 min digestion
was extracted by digitization of published data28 using
WebPlotDigitizer (version 4.2) (WebPlotDigitizer, CA, USA).
3.6. IVIVR and Data Normalization. To evaluate the
results from the biphasic lipolysis experiments and contrast
them with the pH-stat results, IVIVR plots were created for
each of the data sets. In vitro data were evaluated based on the
percentage of the dose (w/w) considered to be bioaccessible
after 60 min digestion. Therefore, biphasic lipolysis data were
evaluated based on the percentage of the dose (w/w) which
had partitioned into the decanol layer after 60 min digestion,
whereas pH-stat data were evaluated based on the percentage
of the dose (w/w) in the aqueous micellar phase of the
digestion media after 60 min digestion. The in vitro results
were compared to the respective in vivo area under the curve
(AUC) values.
In vitro data were normalized to facilitate a direct
comparison of the results from the two experimental setups,
that is, biphasic lipolysis or pH stat. Bioaccessibility data from
each setup were normalized relative to the mean in vitro
bioaccessible percentage (w/w) of the LBFs after 60 min
digestion from the respective in vitro setup. The mean was
calculated using all the bioaccessibility results after 60 min
digestion from each set of LBFs, with a set of LBFs defined as
those which contain the same active pharmaceutical ingredient
and have been tested in the same in vivo study. The applied
normalization equation was as follows
μ′ =X X/
where X′ is the normalized data point, X is the percentage of
the dose (w/w) of the tested LBF considered to be
bioaccessible after 60 min digestion, and μ is the mean of in
vitro bioaccessible percentage (w/w) of the LBF set from the
respective setup (i.e., the same setup as used to measure X)
after 60 min digestion. When a comparison of different in vitro
setups was not the objective of the IVIVR, non-normalized
data would be used to establish predictive relationships
(Supporting Information, Figures S1−S4).
4. RESULTS AND DISCUSSION
4.1. Development of the Biphasic Lipolysis Exper-
imental Method. To improve the efficiency of the LBF
development process, there is a need for a biopredictive and
rapid in vitro lipolysis screening method. In this study, a
biphasic lipolysis method which incorporates dispersion in the
stomach, GI transit, and absorption in the small intestine was
developed. This development of a two-stage biphasic test to
assess the performance of LBFs presents many challenges. The
biphasic method on the inForm instrument was previously
used to test amorphous solid dispersions,25,26 a cyclodextrin
solution,26 and unformulated APIs.26 These previously
validated test conditions were adapted to include the digestion
of the LBFs and to account for the properties of the lipid
excipients included within the LBF. Stirring is an important
factor in biphasic experiments, requiring a balance between
sufficient stirring to ensure dispersion of the LBF in the gastric
phase while minimizing the risk of emulsification of the
decanol phase in the intestinal phase. Therefore, initial method
validation focused on the influence of stirring rate on test
conditions, starting with stirring at 100 rpm in both the gastric
and intestinal sectors, based on previous biphasic experi-
ments.25,26 Based on observations from these previous studies,
stirring speeds of 100 rpm did not induce emulsification of the
decanol layer into the aqueous phase. However, at lower
speeds (i.e., <100 rpm), there was a risk of formation of air
bubbles in the probe windows of the UV fiber-optic dip probes.
In this present study, given the presence of lipid excipients
and postdigestion products in the aqueous phase, there was an
increased risk of emulsification of the decanol layer. Therefore,
initial method validation experiments explored the impact of
study speed on experimental setup. Using a stirring speed of
100 rpm, the separation of the aqueous and decanol layers was
maintained throughout the 1 h duration of the intestinal sector,
with no scattering of light associated with the mixing or
emulsification of the two layers detected in the UV spectra
taken from the decanol layer. To explore the impact across the
range of LBFs involved, a worst-case challenge testing
approach was applied. In terms of an LBF that displayed the
highest risk of emulsification, a type IV (surfactant-only
formulation) was considered the worst case, given that the
higher concentration of surfactants may increase emulsifica-
tion. However, at a stirring speed of 100 rpm using type IV
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formulation, the biphasic layer was maintained through the
experiment, with no decanol layer emulsification.
The other worst-case test condition anticipated was an LBF
that is a poorly dispersible Lipid Formulation Classification
System type I formulation,9 such as a nilotinib olive oil
suspension. An example of the effect of the varying stirring
speed in the gastric phase is shown in Figure 2, which shows
the nilotinib drug concentrations in the decanol phase at both
100 rpm and 300 rpm for an olive oil LFCS type I system. At a
lower stirring speed of 100 rpm in the gastric sector, dispersion
of the formulation was inadequate and direct mixing of the
type I oil into the decanol layer was observed. This was
confirmed analytically, with unexpectedly high quantities of the
drug (>40% of the administered dose) detected within the
decanol layer within 5 min of the transition to the intestinal
phase (Figure 2). On increasing the stirring speed to 300 rpm
in the gastric phase, complete dispersion of the type I LBF was
observed and, quantitatively, the amount of drug appearing in
the decanol layer over the first 5 min of switching to the
intestinal phase was more gradual (i.e., 2.3% after 5 min) and
was therefore considered to more closely mimic the intestinal
absorption process. Thus, the finalized stirring conditions were
established as 300 rpm during the gastric sector of the
experiment. Subsequently, once the decanol layer was added to
transition to the intestinal sector, the stirring speed was
reduced to 100 rpm. The stirring conditions established were
found to be suitable over a range of different types of LBFs
used in the study, ranging from poorly dispersible LFCS type I
systems to surfactant-only LFCS type IV formulations.
Experiments were initially trialed at a single pH (pH 7.5),
simulating only intestinal conditions, matching the standard
pH-stat experiments (Table 2). However, this was found to be
poorly predictive of the in vivo performance of the nilotinib
LBFs. Therefore, a pH shift mimicking the transition from
gastric to intestinal conditions was introduced as a part of the
setup. Level II FaSSIF30 was selected as an appropriate
intestinal fluid because of both its widespread commercial
availability and the ease of preparation. The medium in the
intestinal sector was set to pH 7.5 instead of pH 6.8, which had
been used in previous biphasic experiments,25,26 to match the
pH-stat experiments and reduce the variables when comparing
the results from both the setups.
The performance of the LBFs in the biphasic lipolysis
experiments was determined by the drug concentration of the
drug in the decanol layer, that is, the “absorbed drug”. It was
not possible to quantify the drug concentration in the aqueous
phase using the fiber-optic UV dip probes because of the
turbidity caused by the presence of the lipid formulations and
the pancreatic enzyme extract in the aqueous layer. In addition,
the digestion of lipids by the pancreatic enzyme extract was
measured by the addition of NaOH. The rank order of the
addition of NaOH and free FAs liberated in the biphasic
lipolysis method was broadly similar to the results available
from the pH-stat testing (Supporting Information, Table
S3),11,27 with the extent of digestion during the biphasic
lipolysis experiments shown in Table 3. However, some
differences in the rate and extent of digestion of lipids may be
due to minor differences in the composition of the intestinal
media between the in vitro lipolysis tests and potential
permeation of some postdigestion products into the decanol
layer.
4.2. Nilotinib LBFs. Nilotinib lipid suspensions prepared
with Peceol, olive oil, Capmul MCM, or Captex 1000 were
prepared (Table 1a)27 and subsequently evaluated using the
optimized biphasic in vitro lipolysis method. The results
obtained for the percentage of the nilotinib dose detected in
the absorptive decanol phase are presented in Figure 3. IVIVRs
were created to compare the application of the biphasic
lipolysis and pH-stat methods to predict the in vivo
performance. This comparison of the previously published27
rat in vivo results with the in vitro results from both lipolysis
setups is shown in Table 4 and Figure 4. A strong positive
correlation was established between in vivo bioavailability and
the biphasic in vitro method (R2 = 0.8064). In contrast, the
pH-stat method poorly correlated with in vivo data (R2 =
0.1497).
As nilotinib is a weakly basic drug, supersaturation generated
upon transfer from the stomach to the small intestine is likely
Figure 2. Drug release time profile in the decanol layer for the
nilotinib olive oil suspension, with experiments conducted at a single
pH (pH 7.5). The profiles using gastric stirring speeds of 100 rpm and
300 rpm are shown by the black squares and gray circles, respectively.
Table 3. Amount of FAs (mmol) Liberated after 60 min
Digestion during the Biphasic Lipolysis Experimenta
formulation titrated FAs released after 60 min digestion (mmol)
Nilotinib LBFs
Peceol 0.419 ± 0.037
Capmul MCM 2.437 ± 0.087
Captex 1000 0.245 ± 0.042
olive oil 0.034 ± 0.016
fenofibrate LBFs from the pig study
type IIIA MC 0.929 ± 0.052
type IIIA LC 0.624 ± 0.018
type IIIB/IV 0.282 ± 0.055
fenofibrate LBFs from the human study
E5 (80) 0.797 ± 0.024
E5 (20) 0.744 ± 0.064
MDS 0.432 ± 0.061
danazol LBFs
F1 1.814 ± 0.065
F2 1.305 ± 0.048
F3 0.860 ± 0.070
F4 0.193 ± 0.043
aThe values of titrated FAs represent the values corrected for the level
of FA released in background lipolysis (digestion media alone). Each
data point represents the mean ± standard deviation (SD).
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to be a key factor when considering its oral bioavailability. As
the pH-stat approach for nilotinib LBFs was conducted at a
single pH simulating intestinal conditions (pH 7.5), any
transient supersaturation of weakly basic drugs in the intestine
resulting from an increased solubilization capacity of the gastric
compartment would be overlooked. As the biphasic lipolysis
test incorporates this switch in conditions, the effect of
nilotinib supersaturation should be captured based on drug
appearance in the decanol layer. This improved biomimetic
setup most likely contributed to the improved prediction of the
performance of nilotinib LBFs in the biphasic lipolysis setup.
4.3. Fenofibrate LBFs. The biphasic lipolysis method was
subsequently employed to evaluate two sets of LBFs
containing fenofibrate. The first set was based on formulations
previously evaluated in vivo in pigs, consisting of a type IIIA
MC, a type IIIA LC, and type IIIB/IV fenofibrate lipid
solutions (Table 1b).11 To examine the ability of the biphasic
lipolysis and pH-stat methods to predict the in vivo
performance, an IVIVR was created. The results from the
biphasic lipolysis experiments had a better correlation with the
reported in vivo bioavailability (R2 = 0.9785) than the
conventional pH-stat experiment setup (R2 = 0.0608) (Figures
5 and 6, Table 5). A second study involved three LBFs where
bioavailability data have been reported from a human trial.29
The LBFs were classified as two type IIIA lipid solutions and
one type IIIA micronized lipid suspension (Table 1c). The
biphasic lipolysis method was more highly correlated with the
in vivo bioavailability (R2 = 0.9076) than the pH-stat approach
(R2 = 0.8548) (Figures 7 and 8, Table 6).
As fenofibrate is a neutral compound, it was not anticipated
that the change from the gastric to intestinal pH in the biphasic
lipolysis would have the predominant impact on the ranking of
Figure 3. Drug release time profile in the decanol layer for the
nilotinib LBFs tested in rats. The Peceol, Capmul MCM, olive oil, and
Captex 1000 suspensions are represented by the black circles, gray
squares, red triangles, and blue inverted triangles, respectively. Each
data point represents the mean ± SD (n = 3).








in the decanol layer
after 60 min




phase after 60 min
digestion (n = 3)
Peceol 13,103 ± 2557 36.21 ± 1.49 0.51 ± 0.06
Capmul
MCM
11,210 ± 5476 29.53 ± 1.01 0.99 ± 0.06
Captex
1000
5168 ± 2197 20.09 ± 2.62 0.82 ± 0.09
olive oil 3548 ± 2711 24.18 ± 1.13 0.22 ± 0.03
aEach data point represents the mean ± SD.
Figure 4. IVIVR for the nilotinib LBFs with PK data in rats available.
In vivo bioavailability is plotted as AUC0−inf in Sprague Dawley rats.
27
In vitro data were normalized to facilitate a direct comparison of the
results from different experimental setups. Data were normalized to
the mean drug concentration in the respective in vitro setup. Biphasic
lipolysis data are based on the percentage of the dose partitioned into
the decanol layer after 60 min digestion and are represented by the
black triangles, R2 = 0.8064. pH-stat data are based on the percentage
of the dose in the aqueous micellar phase after 60 min digestion and
are represented by the gray crosses, R2 = 0.1497.
Figure 5. Drug release time profile in the decanol layer for the
fenofibrate LBFs tested in pigs. The type IIIA MC, type IIIA LC, and
type IIIB/IV formulations are represented by the black circles, gray
squares, and red triangles, respectively. Each data point represents the
mean ± SD (n = 3).
Figure 6. IVIVR for the fenofibrate LBFs with PK data in pigs
available.11 In vivo exposure is plotted as Landrace pigs AUC. In vitro
data have been normalized to the mean drug concentration in the
respective in vitro setup. Biphasic lipolysis data are based on the
percentage of the dose partitioned into the decanol layer after 60 min
digestion and are represented by the black triangles, R2 = 0.9786. pH-
stat data are based on the percentage of the dose in the aqueous
micellar phase after 60 min digestion and are represented by the gray
crosses, R2 = 0.0608.
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the LBFs. However, the presence of an absorptive sink was
considered to play the more significant role for fenofibrate,
given the drug’s highly lipophilic characteristics. The pH-stat
experiments on the fenofibrate LBFs (tested in pigs) displayed
substantial differences between the type IIIA and type IIIB/IV
formulations. The type IIIA formulations displayed a limited
drug precipitation (<5%), whereas the type IIIB/IV
formulation displayed an extensive drug precipitation (∼70%
dose) in the pH-stat lipolysis setup. However, this difference
was not observed in the in vivo study, with all three
formulations displaying similar bioavailability in pigs. This
higher-than-expected bioavailability for the type IIIB/IV
formulation would suggest that in vivo there may be a lower
degree of precipitation11,15 and compensatory mechanisms
such that the drug precipitate would quickly redissolve as rapid
drug permeation would maintain sink conditions in the
intestine. Alternatively, the study suggested a key limitation
of the pH-stat approach where there may be a tendency to
overestimate the potential impact of lipolysis-triggered
precipitation because of nonsink conditions.
Thomas et al. have similarly observed large differences
between fenofibrate LBFs during in vitro lipolysis without an
absorption sink, which were not evident in vivo.31 Sassene et al.
studied precipitation from LBFs in the stomach and proximal
duodenum of rats,32 comparing samples from the intestine and
in vitro pH-stat lipolysis testing. No precipitation of drug was
found for fenofibrate in the intestine of the euthanized rats at
any timepoint, which contrasted the pH-stat lipolysis results
for these formulations which showed precipitation under
simulated intestinal conditions. By incorporating an absorptive
sink, our new study in the biphasic lipolysis setup therefore
confirmed that more reliable predictions of the in vivo
performance of LBFs can be achieved particularly for high-
permeable drugs such as fenofibrate.
4.4. Danazol LBFs. We further studied a set of danazol
lipid solutions (2 × type IIIA, 1 × type IIIB, and 1 × type IIIB/
IV) using the biphasic lipolysis setup based on formulations
which had previously been tested in dogs.28 The results from
the biphasic lipolysis showed that the partitioning of danazol
into the decanol layer was in a reversed order to that observed
in vivo (Figures 9 and 10, Table 7). In contrast, the nonsink
pH-stat results from these LBFs achieved a correct rank order
and were highly correlated with the in vivo findings (R2 =
0.9846). To determine if the presence of the gastric sector had
caused the reverse ranking, the biphasic lipolysis experiments
were carried out excluding the gastric sector, thus replicating
the pH profile of the pH-stat experiments. As danazol is a
neutral drug over the physiological pH range, the presence of
the gastric sector was not anticipated to cause the reversed
rankings. Indeed, these experiments without the gastric sector
resulted in the same ranking as the previous biphasic lipolysis
experiments, that is, a reversed order to that reported in vivo.
Another potential reason for the discrepancy could be the
different intestinal media used in the biphasic and pH-stat
lipolysis in vitro testing. Level II FaSSIF was used as the
intestinal medium for biphasic lipolysis testing, which differed
in terms of the bile salt and concentration of the endogenous
Table 5. Overview of the in Vivo and in Vitro Results for the
Fenofibrate LBFs from the Pig Studya
Landrace pigs AUC
[ng·h/mL] (n = 6)11
biphasic lipolysis:
percentage released
in the decanol layer
after 60 min




phase after 60 min
digestion (n = 3)
type IIIA
MC
55,593.0 ± 10659.5 15.38 ± 0.64 92.5 ± 12.0
type IIIA
LC
51,605.3 ± 8348.7 13.73 ± 0.20 66.0 ± 7.1
type
IIIB/IV
56,378.3 ± 15439.5 16.10 ± 0.75 29.0 ± 5.8
aEach data point represents the mean ± SD.
Figure 7. Drug release time profile in the decanol layer for the
fenofibrate LBFs tested in humans. The E5 (80), E5 (20), and MDS
formulations are represented by the black circles, gray squares, and
red triangles, respectively. Each data point represents the mean ± SD
(n = 3).
Figure 8. IVIVR for the fenofibrate LBFs with PK data in humans
available.29 In vivo exposure is plotted as human AUC. In vitro data
have been normalized to the mean drug concentration in the
respective in vitro setup. Biphasic lipolysis data are based on the
percentage of the dose partitioned into the decanol layer after 60 min
digestion and are shown by the black triangles, R2 = 0.9076. pH-stat
data are based on the percentage of the dose in the aqueous micellar
phase after 60 min digestion and are represented by the gray crosses,
R2 = 0.8548.
Table 6. Overview of the in Vivo and in Vitro Results for the












phase after 60 min
digestion (n = 3)
E5
(80)
51.66 ± 22.65 14.55 ± 0.25 6.22 ± 0.75
E5
(20)
52.66 ± 19.23 16.69 ± 0.48 4.67 ± 2.20
MDS 44.52 ± 9.20 11.49 ± 0.42 0.75 ± 0.46
aEach data point represents the mean ± SD.
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surfactants used compared to the pH-stat experiment (Table
2). It may be possible that the rate and extent of digestion of
the formulations differed because of the media composition,
which could lead to differences in their in vitro performance.
However, Kilic and Dressman reported a correct ranking of
formulations using a simplified in vitro lipolysis experiment,
without the presence of a sink, using Level II FaSSIF V2 as the
intestinal medium.33 Level II FaSSIF V2 contains the same
surfactants as Level II FaSSIF with the same concentration of
sodium taurocholate (3 mM) present in both media. This
indicated that the difference in media composition and
subsequent effects on digestion were likely not the primary
reasons causing the difference between the biphasic in vitro
lipolysis results and the in vivo findings.
The reverse ranking was therefore most likely caused by an
excipient-specific effect in the biphasic system. The danazol
LBFs used in the study of Cuine ́ et al.28 used high
concentrations of ethanol as a cosolvent in the formulation.
The partitioning of the drug into the decanol layer broadly
correlated with the concentration of ethanol in the
formulations. The high concentration of ethanol in the
formulations may therefore have resulted in an altered drug
flux into the decanol layer and ethanol-dependent partitioning
effects in the biphasic system compared to the in vivo situation.
Although this seems to be the most likely explanation for the
obtained findings, it cannot be excluded that other
components of the formulations caused further partitioning
effects in vitro of danazol that were not relevant for the in vivo
absorption. It was beyond the scope of this study to evaluate
how each formulation component may affect drug partitioning
into the decanol layer. However, based on current findings, the
biphasic lipolysis test appears highly promising for common
LBFs, but there is a caveat regarding in vivo predictability when
formulations which comprise high levels of cosolvents, such as
ethanol, are studied.
4.5. Limitations of the Study. Although the two-stage
biphasic lipolysis method was an improvement over the
standard pH-stat setup in terms of predicting the effect of GI
transit, there were still aspects which were not fully reflective of
the in vivo process. In the biphasic lipolysis setup, the switch
from gastric to intestinal conditions occurs very rapidly,
whereas in vivo the process of gastric emptying is usually more
gradual.34 This rapid pH transition may lead to an over-
estimation of the precipitation rate. Also, the 1 min delay after
transition to pH 7.5, included to facilitate dispersion of the
pancreatic enzyme prior to the addition of decanol, indicates
that permeation during the initial transient supersaturation
period upon shift to intestinal conditions may not have been
fully captured by the decanol concentration profile. In
addition, the gastric media used in the biphasic lipolysis
experiments did not incorporate gastric lipases. Thus, the
effects of gastric lipolysis were overlooked by the setup.
Furthermore, the surface area of the interface between the
aqueous and decanol layers (approx. 19.63 cm2) was much
lower than the surface area of the small intestine,35 which
limited the in vitro “absorption” of the drug during its brief
supersaturated state. This concern of a limited surface area and
absorptive flux is a more general aspect and also needs
consideration when, for example, Caco-2 cells or a biomimetic
membrane is used to mimic physiological absorption.22−24
Although the biphasic setup was validated using four
different in vivo studies, it should be acknowledged that
there is a paucity of published in vivo studies using LBFs where
significant in vivo differences are observed as a function of
different LBF types. Indeed, in two of the four studies in the
present study, differing lipid formulation types failed to yield
differences in the in vivo bioavailability.11,29 Further mecha-
nistic studies that relate formulation type to in vivo
performance would facilitate more reliable IVIVRs. In addition,
these in vivo studies were conducted using four different
species (rats, pigs, dogs, and humans), whereas the biphasic
setup was not adapted to account for differences between the
species. Therefore, it is possible that interspecies differences in
Figure 9. Drug release time profile in the decanol layer for the
danazol LBFs tested in dogs. The F1, F2, F3, and F4 formulations are
represented by the black circles, gray squares, red triangles, and blue
inverted triangles, respectively. Each data point represents the mean ±
SD (n = 3).
Figure 10. IVIVR for the danazol LBFs with PK data in dogs
available.28 In vivo exposure is plotted as beagle dog AUC0−10h. In vitro
data have been normalized to the mean drug concentration in the
respective in vitro setup. Biphasic lipolysis data are based on the
percentage of the dose partitioned into the decanol layer after 60 min
digestion and are shown by the black triangles, R2 = 0.6559. pH-stat
data are based on the percentage of the dose in the aqueous micellar
phase after 60 min digestion and are represented by the gray crosses,
R2 = 0.9846.
Table 7. Overview of the in Vivo and in Vitro Results for the











percentage released in the
aqueous micellar phase
after 60 min digestion
(n = 3)b
F1 409.5 ± 92.9 15.44 ± 0.43 ∼90.9 ± 4.5
F2 221.5 ± 70.5 16.14 ± 0.34 ∼47.4 ± 1.7
F3 209.4 ± 114.5 18.40 ± 1.14 ∼35.7 ± 4.7
F4 129.6 ± 22.9 22.14 ± 1.25 ∼22.3 ± 2.4
aEach data point represents the mean ± SD. bValues extracted from
the research article figure.
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bioavailability of these drugs may be confounding factors.
Although the majority of other studies investigating LBFs did
not adapt the in vitro lipolysis method depending on the
species used in the in vivo testing, some groups have
successfully adapted methods to match rat lipolysis con-
ditions.36,37
The setup was tested with three different drugs and a wide
variety of LBFs and therefore demonstrates versatility to test a
broad range of LFCS types, including poorly dispersible LFCS
type I systems and surfactant-only LFCS type IV formula-
tions.9 However, testing on the experimental setup was limited
to the types of LBFs explored in this paper and the drugs
utilized. Therefore, for future studies with different drug/LBF
combinations, optimization of the test conditions may need to
be revisited to meet particular challenges of the drug/LBF
combination.
As mentioned in Section 4.1, the turbidity resulting from the
presence of the lipid formulations and the pancreatic enzyme
extract meant that it was not possible to quantify the drug in
the aqueous layer using the in situ fiber-optic dip probes.
However, the use of a nylon mesh around the probe and
immobilized lipase, instead of the pancreatic extract, would
potentially allow quantification of the aqueous drug concen-
trations using the UV fiber-optic dip probes, as outlined very
recently in the work by Alvebratt et al.24 Quantification of the
drug concentrations in the aqueous layer may provide
additional insights into the kinetics of drug concentrations in
this aqueous layer, for example, drug precipitation, and future
approaches that provide an option to quantify the aqueous
concentrations simultaneously with the concentrations in the
absorptive phase are merited.
5. CONCLUSIONS
Overall, the biphasic lipolysis method provided an improved in
vitro prediction of the relative performance of the LBFs
compared to the pH-stat lipolysis method for the majority of
the investigated systems. The pH-stat lipolysis method was
advanced by incorporating a pH shift to mimic GI transfer,
leading to an improvement in the prediction of weak bases,
such as nilotinib LBFs. By including a decanol layer as an
intestinal absorptive sink, the proposed method more reliably
predicted the in vivo performance of fenofibrate LBFs both in
pigs and in humans. In addition, the biphasic lipolysis method
had a superior throughput capacity using fiber-optic dip probes
to assess the performance of the LBF, thus eliminating several
time-consuming procedures such as centrifugation and HPLC
analysis of samples. Because of the automation available on the
platform, much of the human error may be removed from the
experimental process, resulting in highly reproducible results.
Although some further development work is necessary to fully
understand any limitations associated with the setup, such as
the impact of ethanol/cosolvents on drug appearance in the
decanol layer, it has the potential to act as a useful tool in the
formulation development space, facilitating a more efficient
screening process of novel LBFs.
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